Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

3274 - Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNET)


29 Sep 2019


Poster Display session 2


Tumour Site

Neuroendocrine Neoplasms


Shira Sherman


Annals of Oncology (2019) 30 (suppl_5): v564-v573. 10.1093/annonc/mdz256


S. Sherman1, O. Rotem1, A. Zer1, T. Shochat2, E. Dudnik1

Author affiliations

  • 1 Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, 4941492 - Petah Tikva/IL
  • 2 Statistical Consulting Unit, Rabin Medical Center, 49100 - Peth Tikva/IL


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3274


Little is known regarding the efficacy of ICPi in LCNET.


Thirty seven consecutive patients (pts) with advanced LCNET were selected from the Davidoff Cancer Center database. These were divided into Groups A1 (pts treated with ICPi, n-23) and A2 (pts not treated with ICPi, n-14). Another cohort of advanced non-small cell lung cancer (NSCLC) pts treated with nivolumab at five Israeli cancer centers in 2015-2016 was chosen as a comparator (Group B, n-270). ORR, PFS with ICPi in Group A1 were assessed (RECIST 1.1), OS with ICPi was compared between Groups A1 and B. OS since advanced disease diagnosis (OSDx) was compared between Groups A1 and A2.


Baseline pts characteristics are presented in the table. In Group A1* (n-21, 2 pts receiving combined ICPi + chemotherapy were excluded), ORR and median PFS with ICPi were 33%, and 4.2 months (95% CI, 2.4-8.1), respectively. With median follow-up since start of ICPi of 6.2 months [IQR 2.2-12.1] and 4.9 months [IQR 2.3-8.9] in Groups A1* and B, respectively, 52% of pts in Group A1* and 64% of pts in Group B had died. Median OS with ICPi comprised 11.8 months (95% CI, 3.7-NR) and 6.9 months (95% CI, 5.5-8.1) in Groups A1* and B, respectively (p-0.23). Median OSDx was 14.5 months (95% CI, 10.1-38.9) and 10.3 months (95% CI, 2.6-NR), in Groups A1 and A2, respectively (p-0.54). Abbreviations: Tx- treatment, N – nivolumab, P-pembrolizumab, A- atezolizumab.Table: 1403P Baseline patients characteristics

Group A1* (n-21)Group B (n-270)p value
Age (median, range), y62 (45-77)67 (40-99)0.004
Gender, %0.09
Smoking, %1
Never smokers1414
ECOG PS at ICPi, %0.06
Previous Tx lines, %0.2
NA10 (3)
ICPi type: N/P/A/other, %62/9/20/9100/0/0/0NA


In advanced LCNET, ICPi outcomes are comparable to the outcomes observed in advanced NSCLC. Future prospective research is needed to clarify the impact of ICPi on OS in LCNET.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


A. Zer: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca, Roche, BMS, MSD, BI, TAKADA. E. Dudnik: Research grant / Funding (self): Roche, Boehringer Ingelheim; Advisory / Consultancy: Boehringer Ingelheim, Roche, AstraZeneca, Pfizer, MSD, BMS, Novartis, Takeda. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.